NMDA Receptors

GluN2B-NMDAR antagonist-1 is an orally active antagonist of the GluN2B subtype of the N-methyl-D-aspartate receptor (NMDAR). This compound exhibits neuroprotective properties, making it a valuable tool in studying ischemic injury and related neurodegenerative conditions. It is primarily used in research to explore mechanisms of neuronal damage and potential therapeutic interventions.

Simufilam is an orally active modulator of filamin A (FLNA) that restores NMDA receptor (NMDAR) signaling and Arc expression. It effectively inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, which results in improved insulin sensitivity and a reduction in Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. This compound is particularly valuable for research applications focused on Alzheimer's disease and related neurodegenerative disorders.

Co 101244 hydrochloride is a selective antagonist of the NMDA receptor, specifically targeting the NR2B subunit. This compound is utilized in research to investigate the role of NMDA receptors in synaptic plasticity, neurodegeneration, and various neurological disorders. Its properties make it a valuable tool for studying excitatory neurotransmission and the mechanisms underlying synaptic function.

Bupivacaine is an NMDA receptor inhibitor that modulates neuronal excitability by blocking sodium, L-calcium, and potassium channels. It exhibits potent inhibition of SCN5A channels, with an IC50 of 69.5 μM. This compound is primarily utilized in research focused on chronic pain mechanisms and therapeutic interventions.

Bupivacaine-d9 is a deuterium-labeled analog of Bupivacaine, primarily targeting NMDA receptors. This compound exhibits inhibitory effects on sodium, L-calcium, and potassium channels, with a notable potency against SCN5A channels, characterized by an IC50 value of 69.5 μM. Bupivacaine-d9 is utilized in research related to chronic pain mechanisms and the modulation of excitatory neurotransmission, offering valuable insights into therapeutic applications in pain management.

Creatinine acts as a GABAA and NMDA receptor modulator, demonstrating antioxidant properties and metabolic regulation. It is produced through the non-enzymatic conversion of creatine and phosphocreatine in muscle, making its serum levels an important biomarker for renal function, muscle mass, and clinical outcomes. Creatinine is utilized in evaluating perioperative renal risk and has applications in research on neurodegenerative diseases, psychiatric disorders, acute and chronic kidney injury, and renal failure. Additionally, it can induce specific Cryptococcus species to produce creatinine deiminase, highlighting its role in metabolic studies.

Memantine is a noncompetitive antagonist of the N-methyl-D-aspartate receptor (NMDAR). It has been shown to modulate excitotoxicity and is utilized in research studies focused on moderate-to-severe Alzheimer's disease (AD). This compound is essential for exploring pathways related to neurodegeneration and cognitive function.

Orphenadrine hydrochloride is a non-competitive antagonist of the NMDA receptor, effectively crossing the blood-brain barrier with a Ki of 6.0 μM. This compound demonstrates significant biological activity in alleviating stiffness, pain, and discomfort related to muscle strains, sprains, and injuries. Additionally, it serves as an adjunct therapy for tremors in Parkinson’s disease and exhibits neuroprotective properties, making it valuable in research on neurodegenerative disorders.

Procyclidine is a muscarinic receptor antagonist with additional NMDA antagonist properties. It is primarily utilized in research related to Parkinson's disease and associated psychiatric disorders, including Soman-induced epilepsy. Procyclidine’s mechanism of action facilitates investigations into cholinergic dysfunction and therapeutic strategies for movement disorders.